Published in J Virol on February 01, 1990
Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol (1992) 1.62
Two regions of the mouse mammary tumor virus long terminal repeat regulate the activity of its promoter in mammary cell lines. Mol Cell Biol (1991) 1.34
CDP is a repressor of mouse mammary tumor virus expression in the mammary gland. J Virol (2000) 0.99
Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia. Mol Ther (2011) 0.98
Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J Virol (2009) 0.92
Activation of the mouse mdr3 gene by insertion of retroviruses in multidrug-resistant P388 tumor cells. Mol Cell Biol (1993) 0.80
Mouse mammary tumor virus sequences responsible for activating cellular oncogenes. J Virol (1998) 0.77
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature (1984) 5.53
Transcriptional interference in avian retroviruses--implications for the promoter insertion model of leukaemogenesis. Nature (1984) 5.26
Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell (1984) 4.29
Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J (1986) 4.08
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Two proto-oncogenes implicated in mammary carcinogenesis, int-1 and int-2, are independently regulated during mouse development. Proc Natl Acad Sci U S A (1986) 3.34
Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J (1984) 3.28
Potential oncogene product related to growth factors. Nature (1987) 2.53
Four classes of mRNA are expressed from the mouse int-2 gene, a member of the FGF gene family. EMBO J (1988) 2.51
Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J (1985) 2.47
Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact. Cell (1984) 2.44
Concerted activation of two potential proto-oncogenes in carcinomas induced by mouse mammary tumour virus. Nature (1986) 2.24
Expression of the FGF-related proto-oncogene int-2 during gastrulation and neurulation in the mouse. EMBO J (1988) 2.08
Patterns of proviral insertion and deletion in avian leukosis virus-induced lymphomas. J Virol (1986) 1.93
Nucleotide sequence 5' of the chicken c-myc coding region: localization of a noncoding exon that is absent from myc transcripts in most avian leukosis virus-induced lymphomas. Proc Natl Acad Sci U S A (1984) 1.76
Multiple RNAs expressed from the int-2 gene in mouse embryonal carcinoma cell lines encode a protein with homology to fibroblast growth factors. EMBO J (1988) 1.66
Expression pattern of the FGF-related proto-oncogene int-2 suggests multiple roles in fetal development. Development (1989) 1.60
Properties of a mouse ribosomal protein promoter. Proc Natl Acad Sci U S A (1986) 1.42
Transcription of three c-myc exons is enhanced in chicken bursal lymphoma cell lines. Proc Natl Acad Sci U S A (1985) 1.23
Detection and characterization of the fibroblast growth factor-related oncoprotein INT-2. Mol Cell Biol (1989) 1.21
Mesoderm-inducing properties of INT-2 and kFGF: two oncogene-encoded growth factors related to FGF. Development (1989) 1.08
Features of the chicken c-myc gene that influence the structure of c-myc RNA in normal cells and bursal lymphomas. Mol Cell Biol (1986) 1.00
A putative int domain for mouse mammary tumor virus on mouse chromosome 7 is a 5' extension of int-2. J Virol (1989) 0.89
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
What clinical information do doctors need? BMJ (1996) 16.23
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med (2001) 14.84
Informed consent: the intricacies. BMJ (1997) 13.97
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
The failings of NICE. BMJ (2000) 8.50
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol (1982) 6.11
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol Microbiol (1997) 5.47
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters. J Infect Dis (1982) 5.40
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Rationing: the search for sunlight. BMJ (1992) 5.26
Publishing information about patients. BMJ (1995) 5.19
The future of healthcare systems. BMJ (1997) 5.14
Prejudice against doctors and students from ethnic minorities. Br Med J (Clin Res Ed) (1987) 5.12
The war on drugs. BMJ (1996) 5.11
Global information flow. BMJ (2000) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
Where is the wisdom...? BMJ (1991) 4.85
Medicine and the marginalised. They deserve the best, not the poorest, care. BMJ (2000) 4.80
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 4.78
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Time to register randomised trials. The case is now unanswerable. BMJ (1999) 4.55
PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS. BMJ (1999) 4.54
Moving beyond journals: the future arrives with a crash. BMJ (1999) 4.49
Rationing: the debate we have to have. BMJ (1995) 4.47
The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45
Time to redefine authorship. BMJ (1996) 4.39
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Animal research: the need for a middle ground. BMJ (2001) 4.34
Conflict of interest and the BMJ. BMJ (1994) 4.34
Prison medicine: beginning again. BMJ (1992) 4.29
A randomized controlled trial of antibiotics on symptom resolution in patients presenting to their general practitioner with a sore throat. Br J Gen Pract (1997) 4.18
Measuring the social impact of research. BMJ (2001) 4.17
The case for structuring the discussion of scientific papers. BMJ (1999) 4.16
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature (2001) 4.14
Peer review: reform or revolution? BMJ (1997) 4.13
Profile of the GMC: The day of judgment comes closer. BMJ (1989) 4.10
Managing the clinical performance of doctors. A coherent response to an intractable problem. BMJ (1999) 4.08
Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J (1986) 4.08
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
Protein kinase activity associated with polyoma virus middle T antigen in vitro. Cell (1979) 3.78
Profile of the GMC. 1978 and all that. BMJ (1989) 3.76
"Taken from this place and hanged by the neck...". BMJ (1991) 3.72
The rights of patients in research. BMJ (1995) 3.68
All doctors are problem doctors. BMJ (1997) 3.67
The BMJ's website scales up. BMJ (1998) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
How best to organise acute hospital services? BMJ (2001) 3.63
Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis (1998) 3.61
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Netprints: the next phase in the evolution of biomedical publishing. BMJ (1999) 3.60
Microbial colonization of prosthetic devices. II. Scanning electron microscopy of naturally infected intravenous catheters. Zentralbl Bakteriol Mikrobiol Hyg B (1981) 3.53
GMC: approaching the abyss. BMJ (2001) 3.52
The deliberate misdiagnosis of major depression in primary care. Arch Fam Med (1994) 3.46
Pleasing both authors and readers. A combination of short print articles and longer electronic ones may help us do this. BMJ (1999) 3.44
Don't treat shackled patients. BMJ (1997) 3.40
New government, same narrow vision. BMJ (1998) 3.40
The woolwich and erith project. Planning a community health service. Lancet (1966) 3.34
Almost no evidence exists that the internet harms health. BMJ (2001) 3.31
Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell (1979) 3.26
A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol (1997) 3.25
Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24
The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun (1976) 3.22